Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.46 |
| ▸ | KDM4A | O75164 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.46 |
| ▸ | TET3 | O43151 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.44 |
| ▸ | GABRP | O00591 | 2/20 | 0.44 |
| ▸ | GABRD | O14764 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.44 |
| ▸ | GABRE | P78334 | 2/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198527 | 1.00 | CYP1A2 (0.50) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Hydrochloric Acid SCHEMBL1934550 | 0.98 | CYP1A2 (0.48) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Hydrochloric Acid SCHEMBL2257624 | 0.98 | CYP1A2 (0.48) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Sulfuric Acid SCHEMBL1521031 | 0.92 | CYP1A2 (0.43) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Sulfuric Acid SCHEMBL1521033 | 0.92 | CYP1A2 (0.43) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL15405381 | 0.86 | LMNA (0.42) | CYP1A2FOLH1 | |
| SCHEMBL2984814 | 0.84 | CYP1A2 (0.48) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL2984816 | 0.84 | CYP1A2 (0.48) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL14319857 | 0.84 | GABRP (0.43) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL1082587 | 0.83 | FFAR4 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| US-9657079-B2 | Truncated GLP-1 derivatives and their therapeutical use | NOVO NORDISK A/S (DK) | 2017-05-23 | — | — | US | claimed |
| CN-105001108-A | Optical pure 3,4-dimethyl glutamic acid derivative preparation method | UNIV HEBEI SCIENCE & TECH | 2015-10-28 | — | — | CN | claimed |
| EP-2190873-B1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK AS (DK) | 2015-07-22 | — | — | EP | claimed |
| US-9067977-B2 | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK A/S (DK) | 2015-06-30 | — | — | US | claimed |
| US-20140296131-A1 | Truncated GLP-1 Derivatives and Their Therapeutical Use | NOVO NORDISK A/S (DK) | 2014-10-02 | — | — | US | claimed |
| US-20140011732-A1 | Peptides Derivatized with A-B-C-D- and their Therapeutical Use | NOVO NORDISK A/S (DK) | 2014-01-09 | — | — | US | claimed |
| JP-2010538048-A | — | — | 2010-12-09 | — | — | JP | claimed |
| EP-2258702-A2 | Purified compositions of 10-Propargyl-10-Deazaaminopterin and method of using same in the treatment of tumors | Sloan-Kettering Institute For Cancer Research (US) | 2010-12-08 | — | — | EP | claimed |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-11-18 | — | — | US | claimed |
| EP-2190873-A1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | Novo Nordisk A/S (DK) | 2010-06-02 | — | — | EP | claimed |
| EP-2190460-A1 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE | Novo Nordisk A/S (DK) | 2010-06-02 | — | — | EP | claimed |
| WO-2009030771-A1 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2009-03-12 | — | — | WO | claimed |
| WO-2009030774-A1 | TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2009-03-12 | — | — | WO | claimed |
| EP-1891957-A1 | Purified Compositions of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same in the Treament of Tumors | Sloan-Kettering Institute for Cancer Research (US) | 2008-02-27 | — | — | EP | claimed |
| EP-0506207-B1 | Pharmaceutical vehicles for reducing transdermal flux | ACCESS PHARMA INC (US) | 1999-11-17 | — | — | EP | claimed |
| EP-0872248-A2 | Pharmaceutical vehicles for reducing transdermal flux | Access Pharmaceuticals, Inc. (US) | 1998-10-21 | — | — | EP | claimed |
| EP-0506207-A2 | Pharmaceutical vehicles for reducing transdermal flux | CHEMEX PHARMACEUTICALS, Inc. (US) | 1992-09-30 | — | — | EP | claimed |
| US-4895727-A | Using water soluble zinc compound | CHEMEX PHARMACEUTICALS, INC. (US) | 1990-01-23 | — | — | US | claimed |
| EP-0259133-A2 | Use of organic buffers to reduce dehydroascorbic acid interference in analytical methods | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1988-03-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011732-A1 | Peptides Derivatized with A-B-C-D- and their Therapeutical Use | GLP1R, IAPP, GIPR | CYP1A2 3450/4885TET2 4544/4885KDM4A 3170/4885 |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | GLP1R, GIPR, IAPP | CYP1A2 3675/4885TET2 1250/4885KDM4A 331/4885 |
| US-20140296131-A1 | Truncated GLP-1 Derivatives and Their Therapeutical Use | GLP1R, GIPR, IAPP | CYP1A2 3577/4885TET2 1488/4885KDM4A 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.